Clinical trials

#Biomedical research #Clinical trials #Laboratory data #Long Covid #Neuroscience #Oncology #Trial data

New DDW Highlights episode now available

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The most impactful drug discovery news this week is all linked with scientific research… Read More

#News

#Biomedical research #Clinical trials #Laboratory data #Long Covid #Neuroscience #Oncology #Trial data

This week in drug discovery (17-21 July)  

News round-up for 17-21 July by DDW Digital Content Editor Diana Spencer. The most impactful drug discovery news this week is all linked with scientific research data. Analysts Phesi revealed that a third of clinical development programmes are cancelled during Phase II, and there were significant… Read More

#News

Alzheimer's disease
#Alzheimer's #Clinical trials #Eli Lilly #Neuroscience

Donanemab significantly slowed decline in early Alzheimer’s disease trial 

Eli Lilly has announced positive results of the TRAILBLAZER-ALZ 2 Phase III study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease.   Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer’s Disease… Read More

#News #Trending News

ESG cloud icon green earth concept for environment
#Clinical trials #Diversity #ESG #Healthcare #ICON

Exclusive insight from ICON Cares 2022 ESG Report 

ICON, a healthcare intelligence and clinical research organisation, recently released its ICON Cares 2022 Environmental, Social and Governance (ESG) Report. Diarmaid Cunningham, Chief Administrative Officer at ICON, shares insight with DDW.  At ICON, we engage with our key stakeholders through a variety of methods and the environmental,… Read More

#Business & Investment #Exclusive Content #Regulatory

#AI / data analytics / healthtech / informatics #Clinical trial design #Clinical trials #Oncology #Phase II trial

A third of clinical trials cancelled during Phase II

Analysis of 13,490 clinical trials finds almost a third have been cancelled during Phase II amidst an overall decline in clinical development productivity. Data analytics company Phesi has released the results of its mid-year global analysis of all clinical trials conducted in 2023 to date. Read More

#News #Trending News

Human heart
#Cancer research #Clinical trials #Heart failure #Liver disease #Sequana Medical

Sequana announces first patient enrolled in heart failure trial 

Sequana Medical, a company targeting fluid overload in liver disease, heart failure and cancer, has enrolled the first patient in its MOJAVE study.  MOJAVE, a randomised controlled Phase I/IIa study in the US, will evaluate the safety and efficacy of the company’s second-generation DSR product (DSR 2.0)… Read More

#News

Gram positive cocci in chain bacteria, Streptococcus, a type of bacteria
#Biotechnology #Clinical trials #Group B Streptococcus #Immunology / Virology & Vaccines #MinervaX #Streptococcus

Full enrolment for Phase I clinical trial of Group B streptococcus  

MinervaX, a Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has completed enrolment and initial dosing in its Phase I clinical vaccine trial in older adults. The trial is taking place at CEVAC (Centre for Vaccinology), Ghent University, Belgium.  GBS is most… Read More

#News

Magic mushrooms
#Clinical trial design #Clinical trials #FDA #Psychedelics

FDA recommendations to inform psychedelic drug development

The US Food and Drug Administration (FDA) has published new draft guidance to highlight fundamental considerations to researchers investigating the use of psychedelic drugs for the potential treatment of medical conditions, including psychiatric or substance use disorders. This is the first FDA draft guidance that presents… Read More

#News #Regulatory

#Cancer research #Clinical trial design #Clinical trials #FDA #Phase I trial

New DDW Highlights podcast for 12 June 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  There has been some interesting news related to clinical trials this week, with the announcement that… Read More

#News

#Cancer research #Clinical trial design #Clinical trials #FDA #Phase I trial

This week in drug discovery (5-9 June)

News round-up for 5-9 June by DDW Digital Content Editor Diana Spencer. There has been some interesting news related to clinical trials this week, with the announcement that the FDA has published draft guidance to modernise the design and conduct of studies, and the failure of… Read More

#News

FDA
#AI / data analytics / healthtech / informatics #Clinical trial design #Clinical trials #Digitalisation #FDA

FDA announces additional steps to modernise clinical trials

The US Food and Drug Administration has published draft guidance with updated recommendations for good clinical practices (GCPs) to modernise the design and conduct of clinical trials. The updates are intended to help pave the way for more efficient clinical trials. The draft guidance is… Read More

#Editor's Choice #News #Regulatory

Antibodies attack cancer cell
#ASCO #Cancer research #Clinical trials #Events #Oncology

Four breakthroughs in cancer research revealed at ASCO 2023

Ground-breaking data from several key cancer trials were announced at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. ADAURA Phase III trial The trial assessed Tagrisso (osimertinib) as an adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated… Read More

#Cancer Research #News #Trending News

Laboratory research
#Antibody #ASCO #Cancer research #Clinical trials #Immunotherapy #Janssen #Oncology #T cell activation

Janssen updates ASCO 2023 on oncology pipeline

Janssen has presented new data from across its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Talquetamab Talquetamab is an investigational GPRC5D-directed bispecific antibody currently in clinical development. Updated results from the Phase II MonumenTAL-1 study show that… Read More

#Cancer Research #News #Trending News

Heart
#Cardioprotection #Clinical trials #Heart attack #Pharmaceuticals

Successful Phase I results for cardioprotective drug 

Serca Pharmaceuticals, a cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, has presented data on a novel approach to modulate the beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that… Read More

#News

Clinical trial
#Biotechnology #Chemotherapy #Clinical trials #Immunotherapy

Data shows significant results in cancer-associated fibrosis models 

Redx, a clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic disease, announced preclinical data for its lead fibrosis asset, RXC007, and the Discodin Domain Receptor (DDR)1/2 discovery programme.   The data were from preclinical models of… Read More

#News

#Clinical research #Clinical trials #Drug discovery #Precision medicine

New podcast on how precision medicine will transform clinical trials

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas is in conversation with… Read More

#News